Free Trial
NASDAQ:ADVB

Advanced Biomed Q3 2026 Earnings Results & Report

Advanced Biomed logo
$4.93 -0.21 (-4.07%)
Closing price 03:59 PM Eastern
Extended Trading
$4.90 -0.03 (-0.63%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Advanced Biomed reported Q3 2026 earnings on May 16, 2026. The company reported EPS of -$0.38.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Advanced Biomed EPS Results

Actual EPS
-$0.38
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Advanced Biomed Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Advanced Biomed Q3 2026 Earnings FAQ

Advanced Biomed (NASDAQ:ADVB) reported earnings of -$0.38 per share for Q3 2026. The report was announced on Saturday, May 16, 2026.

Advanced Biomed Earnings Headlines

Advanced Biomed Delays Annual 10-K Filing
Advanced Biomed Inc ADVB
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
ADVB Advanced Biomed Inc.
See More Advanced Biomed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Advanced Biomed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Advanced Biomed and other key companies, straight to your email.

About Advanced Biomed

Advanced Biomed (NASDAQ:ADVB) is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review. Publicly available information about the company’s broader commercial operations, geographic reach, and leadership is limited.

View Advanced Biomed Profile